2017 Clinical Research Grant recipients announced

The WFH is happy to announce the 2017 Clinical Research Grant recipients. Research grants are awarded to outstanding international investigators conducting important clinical and diagnostic research with global implications.

Congratulations to the 2017 winners!

Ruchika Goel
New York Presbyterian Hospital, Weill Cornell Medicine, New York, U.S.A.


Identification of Age Varying Co-Morbidities and Predictors of Mortality in Persons with Hemophilia A and B and Derivation of a Mortality Risk Prediction Score.


The objective of this project is to identify the risk-stratified predictors of mortality in pediatric and adult patients with hemophilia A and B. The aim is to be able to assess the longevity, as well as risk factors, for death in patients with hemophilia in the current era of hemophilia treatment center based care and without the effects of HIV and HCV, and assess the mortality predictors compared with a person with a normal life expectancy.

Maria Eulalia Landro
Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina


Platelet Rich Plasma for Synovitis Treatment in Patients with Haemophilia


The aim of this study is to describe the effect of platelet rich plasma (PRP) treatment injected into the joint (intra-articular), in chronic synovitis of the joints in patients with haemophilia, and compare the results with those already known of radioactive synovectomy, chemical synovectomy, synoviangiolysis, and arthroscopic synovectomy. The study will look at the advantages, disadvantages and cost of each procedure, and will compare the results with the intra-articular injection of PRP.

Silvia Spena
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy


Non-Invasive Prenatal Diagnosis of Hemophilia in Male Fetal Cells Circulating in the Maternal Blood


The central hypothesis is that targeting a specific male marker (i.e., a protein expressed only in male cells) will allow the identification of any fetal cells circulating among female (maternal) ones and therefore increase the amount of fetal cells to undergo non-invasive prenatal diagnosis. The researchers plan to test their central hypothesis, and therefore attain the objective of this application by pursuing the following specific aims:

Aim 1. To study the binding of mRPS4Ys to male ribosomes.

Aim 2. To investigate the efficiency of mRPS4Y1s to identify the male fetal cells circulating into maternal blood.

Aim 3. To confirm/exclude the haemophilia-A causing mutation in the isolated fetal cells.

Karin P.M. van Galen
University Medical Center Utrecht, Utrecht, the Netherlands


Pregnancy and Inherited Bleeding Disorders, the PRIDE study


The purpose of the PRIDE project is to implement a new management strategy for women with von Willebrand disease (VWD) and hemophilia carriers in a nationwide prospective observational study. This strategy includes a more physiologic target level of 150 IU/dL to correct clotting factor levels at delivery, pre-emptive and prolonged use of tranexamic acid, and early, aggressive PPH treatment. The strategy will be incorporated into routine clinical practice by means of an electronic delivery plan, made available to the patient and health care providers.